FHIR IG analytics| Package | hl7.fhir.uv.genomics-reporting.r4b |
| Resource Type | Task |
| Id | Task-PGxRecEx02.json |
| FHIR Version | R4B |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Task PGxRecEx02
status: Requested
intent: proposal
code: Consider alternative medication
description: voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.
for: Adam B. Everyman Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, ))
reasonReference: Poor metabolizer
FHIR
FHIRsmith{
"resourceType": "Task",
"id": "PGxRecEx02",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"
]
},
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"status": "requested",
"intent": "proposal",
"code": {
"coding": [
{
"system": "http://loinc.org",
"code": "LA26421-0",
"display": "Consider alternative medication"
}
]
},
"description": "voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.",
"for": {
"reference": "Patient/CGPatientExample01"
},
"reasonReference": {
"reference": "Observation/TxImp02",
"display": "Poor metabolizer"
}
}